Prelude Therapeutics director gets 38,000 share options

Prelude Therapeutics Inc reported that director Katina Dorton received a grant of stock options covering 38,000 shares of common stock.

Rhea-AI Filing Summary

Prelude Therapeutics Inc reported that director Katina Dorton received a grant of stock options covering 38,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 8, 2036.

The award will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as Dorton continues providing service to the company through the vesting date. Following this grant, she holds options for 38,000 shares directly.

Insider Trade Summary

Grant/Award: 38,000 shares

Grant/Award 1 txn

Insider Dorton Katina

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	38,000	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 38,000 contracts (Direct)

Footnotes (1)

1. F1. The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Option grant size: 38,000 options Exercise price: $3.94 per share Expiration date: June 8, 2036 +2 more

5 metrics

Option grant size 38,000 options Director stock option award to Katina Dorton

Exercise price $3.94 per share Strike price for director stock options

Expiration date June 8, 2036 Option term end for director grant

Shares underlying options 38,000 shares Common stock underlying the director options

Post-grant derivative holdings 38,000 options Total options held directly after transaction

Key Terms

Director Stock Option (Right to Buy), exercise price, expiration date, grant, award, or other acquisition, +1 more

5 terms

Director Stock Option (Right to Buy) financial

"security_title: "Director Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "3.9400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-08T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vesting financial

"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Prelude Therapeutics (PRLD) disclose in this Form 4 for Katina Dorton?

Prelude Therapeutics reported a director stock option grant to Katina Dorton. She received options for 38,000 common shares as compensation, with vesting tied to continued service and no open-market share purchases or sales reported.

How many Prelude Therapeutics (PRLD) options were granted to director Katina Dorton?

Katina Dorton was granted options covering 38,000 shares of Prelude Therapeutics common stock. These options give her the right to buy shares at a fixed exercise price if and when they vest and she chooses to exercise.

What is the exercise price and expiration date of Katina Dorton’s PRLD options?

The granted options have an exercise price of $3.94 per share and an expiration date of June 8, 2036. This means she can buy shares at $3.94 any time after vesting and before that expiration date, subject to plan terms.

When do Katina Dorton’s Prelude Therapeutics (PRLD) options vest?

The options will fully vest on the earlier of Prelude’s next annual stockholder meeting or the one-year anniversary of the grant date. Vesting is conditioned on Katina Dorton continuing to provide service to the company on each applicable vesting date.

Is Katina Dorton buying or selling Prelude Therapeutics (PRLD) shares in this Form 4?

This Form 4 reports a grant of stock options, not an open-market stock trade. Dorton acquired derivative securities as compensation and did not report any purchases or sales of Prelude Therapeutics common shares in the market.

How many Prelude Therapeutics (PRLD) options does Katina Dorton hold after this grant?

After this reported transaction, Katina Dorton holds options for 38,000 shares of Prelude Therapeutics common stock directly. This filing does not show additional derivative positions beyond this new award in the derivative summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dorton Katina

(Last) (First) (Middle)

C/O PRELUDE THERAPEUTICS INCORPORATED

175 INNOVATION BOULEVARD

(Street)

WILMINGTON DELAWARE 19805

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Prelude Therapeutics Inc [ PRLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$3.94	06/09/2026		A		38,000		(1)	06/08/2036	Common Stock	38,000	$0.00	38,000	D

Explanation of Responses:

1. The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

	/s/ Bryant D. Lim, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)